The short-term effect and safety of anti-malignant ascites treated with intraperitoneal injection of bevacizumab

doi:10.3877/cma.j.issn.2095-3224.2016.05.011

Abstract

Abstract:

Objective

To investigate the short-term effect and safety of anti-malignant ascites treated with intraperitoneal injection of bevacizumab.

Methods

46 colorectal cancer patients with uncontrolled malignant ascites at the A?liated Hospital of Guilin Medical College from 2010 to 2014 were enrolled in this study. Investigate the VEGF value of malignant ascites and analyze the survival time of two groups.

Results

The mean VEGF value of control group is 671.8±499.15 pg/mL, and has not statistically significant than treatment group (mean value: 1225.11±609.71 pg/mL). In treat group, the mean VEGF value is 1225.11±609.71 pg/mL before treatment. The median survival time of non-paracentesis is 6 months (1~21 months). In contrast with control group, the time of non-paracentesis is significantly longer in treatment group (6.328, P<0.05). After treatment, the mean VEGF value is 317.69±172.14 pg/mL in treatment group. There is statistically significant than control group. In survival analysis, treatment group shows signi?cantly better overall survival (OS) (P<0.05).

Conclusion

For a part of appropriate patients, treated with intraperitoneal injection of bevacizumab is an effective and safety method.

Key words: Colorectal neoplasm, Therapy, Anti-VEGF, Bevacizumab, Malignant ascites

Li Zhong, Zhi Zhao, Xiaobao Zhu, Fulin Ran, Xiao Chen. The short-term effect and safety of anti-malignant ascites treated with intraperitoneal injection of bevacizumab[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(05): 424-427.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.05.011

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I05/424

Figures/Tables 3

References 17

[1]	Torre LA,Bray F,Siegel RL, et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians, 2015, 65(2): 87-108.
[2]	Sinclair P,Singh A,Riaz AA, et al. An unsolved conundrum: the ideal follow-up strategy after curative surgery for colorectal cancer. Gastrointestinal endoscopy, 2012, 75(5): 1072-1079.
[3]	Becker G,Galandi D,Blum HE. Malignant ascites: systematic review and guideline for treatment. European journal of cancer, 2006, 42(5): 589-597.
[4]	Montero E,Miguel J,Lopez-Alvarez J. Care of patients with ascites. The New England journal of medicine, 1994, 330(25): 1828.
[5]	Liu Y,Luan L,Wang X. A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation. OncoTargets and therapy, 2015, 8: 1061-1068.
[6]	Hurwitz HI,Fehrenbacher L,Hainsworth JD, et al. Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. Journal of Clinical Oncology, 2005, 23(15): 3502-3508.
[7]	Adam RA,Adam YG. Malignant ascites: past, present, and future. Journal of the American College of Surgeons, 2004, 198(6): 999-1011.
[8]	Saada E,Follana P,Peyrade F, et al. Pathogenesis and management of refractory malignant ascites. Bulletin du cancer, 2011, 98(6): 679-687.
[9]	Yabushita H,Shimazu M,Noguchi M, et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncology Reports, 2003, 10(1): 89-95.
[10]	Atanackovic D,Cao Y,Kim J-W, et al. The local cytokine and chemokine milieu within malignant effusions. Tumor Biology, 2008, 29(2): 93-104.
[11]	Cavazzoni E,Bugiantella W,Graziosi L, et al. Malignant ascites: pathophysiology and treatment. International journal of clinical oncology, 2013, 18(1): 1-9.
[12]	Smolle E,Taucher V,Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer research, 2014, 34(4): 1553-1561.
[13]	Brown PD. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul, 1995, 35: 293-301.
[14]	Folkman J. Tumor angiogenesis: therapeutic implications. The New England journal of medicine, 1971, 285(21): 1182-1186.
[15]	Numnum TM,Rocconi RP,Whitworth J, et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecologic Oncology, 2006, 102(3): 425-428.
[16]	el-Shami K,Griffiths E,Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. The oncologist, 2007, 12(5): 518-523.
[17]	Pichelmayer O,Zielinski C,Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. New England Journal of Medicine, 2005, 353(7): 740-741.

组别	例数	血清VEGF（pg/mL）	无穿刺生存时间（月）
对照组	20	671. 8±499. 15	2. 75±1. 44
治疗组	26	665. 19±499. 15	6. 92±3. 47
t值	?	10. 246	6. 328
P值	?	0. 965	<0. 001

组别	例数	血清VEGF（pg/mL）	无穿刺生存时间（月）
对照组	20	671. 8±499. 15	2. 75±1. 44
治疗组	26	665. 19±499. 15	6. 92±3. 47
t值	?	10. 246	6. 328
P值	?	0. 965	<0. 001

组别	例数	血清VEGF（pg/mL）	腹水VEGF（pg/mL）
治疗前	26	665. 19±499. 15	1225. 11±609. 71
治疗后	26	170. 61±115. 92	317. 69±172. 14
t值	?	5. 841	4. 332
P值	?	<0. 001	<0. 001

组别	例数	血清VEGF（pg/mL）	腹水VEGF（pg/mL）
治疗前	26	665. 19±499. 15	1225. 11±609. 71
治疗后	26	170. 61±115. 92	317. 69±172. 14
t值	?	5. 841	4. 332
P值	?	<0. 001	<0. 001

Please choose a citation manager

Content to export